SEC Form 4 · accession 0000891293-16-000109
CTI BIOPHARMA CORP · CTIC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack W Singer
Officer — EVP, Chief Scientific Officer · Director
Period of report
Feb 26, 2016
Accepted (ET)
Feb 26, 2016 · 5:44 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000891293
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 26, 2016 | S | 100 | $0.615 | D | 1,054,892 | D | |
| Common Stock | Feb 26, 2016 | S | 300 | $0.618 | D | 1,054,592 | D | |
| Common Stock | Feb 26, 2016 | S | 200 | $0.62 | D | 1,054,392 | D | |
| Common Stock | Feb 26, 2016 | S | 510 | $0.622 | D | 1,053,882 | D | |
| Common Stock | Feb 26, 2016 | S | 100 | $0.623 | D | 1,053,782 | D | |
| Common Stock | Feb 26, 2016 | S | 200 | $0.624 | D | 1,053,582 | D | |
| Common Stock | Feb 26, 2016 | S | 200 | $0.625 | D | 1,053,382 | D | |
| Common Stock | Feb 26, 2016 | S | 300 | $0.63 | D | 1,053,082 | D | |
| Common Stock | Feb 26, 2016 | S | 100 | $0.631 | D | 1,052,982 | D | |
| Common Stock | Feb 26, 2016 | S | 600 | $0.633 | D | 1,052,382 | D | |
| Common Stock | Feb 26, 2016 | S | 3,990 | $0.634 | D | 1,048,392 | D | |
| Common Stock | Feb 26, 2016 | S | 600 | $0.635 | D | 1,047,792 | D | |
| Common Stock | Feb 26, 2016 | S | 1,130 | $0.636 | D | 1,046,662 | D | |
| Common Stock | Feb 26, 2016 | S | 2,600 | $0.637 | D | 1,044,062 | D | |
| Common Stock | Feb 26, 2016 | S | 3,270 | $0.638 | D | 1,040,792 | D | |
| Common Stock | Feb 26, 2016 | S | 200 | $0.639 | D | 1,040,592 | D | |
| Common Stock | Feb 26, 2016 | S | 100 | $0.642 | D | 1,040,492 | D | |
| Common Stock | Feb 26, 2016 | S | 500 | $0.643 | D | 1,039,992 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sale was effected pursuant to a Rule 10b5-1 trading plan.